Tweet
BMC Infect Dis. 2018 Oct 16;18(1):519. doi: 10.1186/s12879-018-3423-z.
Oseltamivir in pregnancy and birth outcomes.
Ehrenstein V1, Kristensen NR2, Monz BU3, Clinch B4, Kenwright A4, S?rensen HT2.
Author information
Abstract
BACKGROUND:
Prenatal exposure to influenza or fever is associated with risk of congenital malformations. Oseltamivir is used to treat influenza and to provide post-exposure prophylaxis. We examined the association between oseltamivir use during pregnancy and birth outcomes.
METHODS:
This was a nationwide registry-based prevalence study with individual level data linkage, in a setting of universal health care access. We included all recorded pregnancies in Denmark in 2002-2013, and used data from population registries to examine associations between dispensings for oseltamivir during pregnancy (first trimester, second/third trimester, none) and congenital malformations, foetal death, preterm birth, foetal growth, and low 5-min Apgar score. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using propensity score matching.
RESULTS:
The study included 946,176 pregnancies. Of these, 449 had first-trimester exposure and 1449 had second/third-trimester exposure to oseltamivir. Adjusted ORs following first-trimester exposure were 0.94 (95% CI 0.49 to 1.83) for any major congenital malformation and 1.75 (95% CI 0.51 to 5.98) for congenital heart defects, based on 7 exposed cases. The association with congenital heart defects was present for etiologically implausible exposure periods and for known safe exposures. There was no evidence of an association between prenatal exposure to oseltamivir and any of the other birth outcomes assessed.
CONCLUSIONS:
The study does not provide evidence of risk associated with oseltamivir treatment additional to that associated with influenza infection.
KEYWORDS:
Congenital abnormalities; Epidemiology; H1N1 influenza; Oseltamivir
PMID: 30326840 DOI: 10.1186/s12879-018-3423-z
Free full text
Oseltamivir in pregnancy and birth outcomes.
Ehrenstein V1, Kristensen NR2, Monz BU3, Clinch B4, Kenwright A4, S?rensen HT2.
Author information
Abstract
BACKGROUND:
Prenatal exposure to influenza or fever is associated with risk of congenital malformations. Oseltamivir is used to treat influenza and to provide post-exposure prophylaxis. We examined the association between oseltamivir use during pregnancy and birth outcomes.
METHODS:
This was a nationwide registry-based prevalence study with individual level data linkage, in a setting of universal health care access. We included all recorded pregnancies in Denmark in 2002-2013, and used data from population registries to examine associations between dispensings for oseltamivir during pregnancy (first trimester, second/third trimester, none) and congenital malformations, foetal death, preterm birth, foetal growth, and low 5-min Apgar score. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using propensity score matching.
RESULTS:
The study included 946,176 pregnancies. Of these, 449 had first-trimester exposure and 1449 had second/third-trimester exposure to oseltamivir. Adjusted ORs following first-trimester exposure were 0.94 (95% CI 0.49 to 1.83) for any major congenital malformation and 1.75 (95% CI 0.51 to 5.98) for congenital heart defects, based on 7 exposed cases. The association with congenital heart defects was present for etiologically implausible exposure periods and for known safe exposures. There was no evidence of an association between prenatal exposure to oseltamivir and any of the other birth outcomes assessed.
CONCLUSIONS:
The study does not provide evidence of risk associated with oseltamivir treatment additional to that associated with influenza infection.
KEYWORDS:
Congenital abnormalities; Epidemiology; H1N1 influenza; Oseltamivir
PMID: 30326840 DOI: 10.1186/s12879-018-3423-z
Free full text